financetom
Business
financetom
/
Business
/
Colgate-Palmolive's Growth Outlook to Outpace Peers Despite Q4 Weakness, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Colgate-Palmolive's Growth Outlook to Outpace Peers Despite Q4 Weakness, Morgan Stanley Says
Feb 3, 2025 9:19 AM

11:47 AM EST, 02/03/2025 (MT Newswires) -- Colgate-Palmolive's ( CL ) Q4 organic sales growth was weaker than expected, but Morgan Stanley remains optimistic about its long-term trajectory, expecting the company to outpace most peers in organic sales growth.

The firm noted in a Monday note that Colgate-Palmolive's ( CL ) 2025 EPS guidance was better than expected, driven by pricing strategies and past reinvestment. However, cost pressures and foreign exchange risks make the lower end of guidance seem more achievable.

"We are more bullish than most investors we spoke with and believe that Colgate-Palmolive ( CL ) will be a 4% organic sales growth company going forward, supported by pricing power and market share gains," Morgan Stanley added.

The firm added that Colgate-Palmolive's ( CL ) global toothpaste market share dipped slightly due to foreign exchange-driven mix effects, while Hill's Pet Nutrition contributed to overall growth, despite European weakness.

Morgan Stanley reduced its price target of Colgate-Palmolive's ( CL ) stock to $104 from $111 and has an overweight rating.

Price: 86.33, Change: -0.37, Percent Change: -0.43

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dr. Reddy's Agrees to Partial Deferral of Cancer Therapy-Related Milestone Payment by Citius Oncology
Dr. Reddy's Agrees to Partial Deferral of Cancer Therapy-Related Milestone Payment by Citius Oncology
Sep 13, 2024
12:14 PM EDT, 09/13/2024 (MT Newswires) -- Citius Oncology ( CTOR ) said Friday that Dr. Reddy's Laboratories (RDY) agreed to a partial deferral without penalty of a milestone payment by Citius that was triggered upon the US Food and Drug Administration's approval of the Lymphir cancer therapy. The milestone payment was due Sept. 9, Citius said in a filing...
Update: Exro Technologies Closes $25-Million Share-Unit Offering
Update: Exro Technologies Closes $25-Million Share-Unit Offering
Sep 13, 2024
12:14 PM EDT, 09/13/2024 (MT Newswires) -- Exro Technologies ( EXROF ) said Friday it raised $25 million after closing a share-unit offering priced at $0.35 apiece. The company will use the proceeds to boost growth in deliveries of its propulsion system technologies to commercial vehicle original equipment manufacturers, as well as coil driver innovation programs with major players in...
Ratings agency Fitch says an extended strike at Boeing poses downgrade risk
Ratings agency Fitch says an extended strike at Boeing poses downgrade risk
Sep 13, 2024
Sept 13 (Reuters) - Global ratings agency Fitch said on Friday an extended strike at Boeing ( BA ) could pose a risk for a credit ratings downgrade. ...
Chinese courier delivery firm BingEx files for US IPO
Chinese courier delivery firm BingEx files for US IPO
Sep 13, 2024
Sept 13 (Reuters) - Chinese courier delivery firm BingEx, which brands its services as 'FlashEx', has filed to go public in the United States, a regulatory filing showed on Friday. WHY IT'S IMPORTANT Several high-profile companies are trying to test investor appetite for IPOs following a prolonged downturn due to rising interest rates and geopolitical turmoil. The number of Chinese...
Copyright 2023-2026 - www.financetom.com All Rights Reserved